Selected article for: "ace inhibition and acute respiratory"
Author: Madan, Taruna; Biswas, Barnali; Varghese, Praveen M.; Subedi, Rambhadur; Pandit, Hrishikesh; Idicula-Thomas, Susan; Kundu, Indra; Rooge, Sheetalnath; Agarwal, Reshu; Tripathi, Dinesh M.; Kaur, Savneet; Gupta, Ekta; Gupta, Sanjeev K.; Kishore, Uday
Title: A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples
  • Cord-id: d1ra9jzd
  • Document date: 2020_12_18
    • ID: d1ra9jzd
    Snippet: Rationale COVID-19 is an acute infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human surfactant protein D (SP-D) is known to interact with spike protein of SARS-CoV, but its immune-surveillance against SARS-CoV-2 is not known. Objective This study aimed to examine the potential of a recombinant fragment of human SP-D (rfhSP-D) as an inhibitor of replication and infection of SARS-CoV-2. Methods rfhSP-D interaction with spike protein of SARS-CoV-2 and
    Document: Rationale COVID-19 is an acute infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human surfactant protein D (SP-D) is known to interact with spike protein of SARS-CoV, but its immune-surveillance against SARS-CoV-2 is not known. Objective This study aimed to examine the potential of a recombinant fragment of human SP-D (rfhSP-D) as an inhibitor of replication and infection of SARS-CoV-2. Methods rfhSP-D interaction with spike protein of SARS-CoV-2 and hACE-2 receptor was predicted via docking analysis. The inhibition of interaction between spike protein and ACE-2 by rfhSP-D was confirmed using direct and indirect ELISA. The effect of rfhSP-D on replication and infectivity of SARS-CoV-2 from clinical samples was studied by measuring the expression of RdRp gene of the virus using qPCR. Measurements and Main Results In-silico interaction studies indicated that three amino acid residues in the RBD of spike of SARS-CoV-2 were commonly involved in interacting with rfhSP-D and ACE-2. Studies using clinical samples of SARS-CoV-2 positive cases (asymptomatic, n=7 and symptomatic, n=8 and negative controls n=15) demonstrated that treatment with 5μM rfhSP-D inhibited viral replication by ~5.5 fold and was more efficient than Remdesivir (100 μM). Approximately, a 2-fold reduction in viral infectivity was also observed after treatment with 5μM rfhSP-D. Conclusions These results conclusively demonstrate that the calcium independent rfhSP-D mediated inhibition of binding between the receptor binding domain of the S1 subunit of the SARS-CoV-2 spike protein and human ACE-2, its host cell receptor, and a significant reduction in SARS-CoV-2 infection and replication in-vitro.

    Search related documents:
    Co phrase search for related documents
    • absorbance significant difference and acute respiratory: 1
    • absorbance significant difference and acute respiratory infection: 1
    • acute respiratory and lung location: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lung tissue damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and luria bertani: 1
    • acute respiratory and luria bertani medium: 1
    • acute respiratory and lysate system: 1
    • acute respiratory and lysis buffer: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory infection and lung location: 1
    • acute respiratory infection and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory infection and lung tissue damage: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory infection and lysis buffer: 1
    • lung tissue and lysis buffer: 1, 2, 3
    • luria bertani and lysis buffer: 1
    • luria bertani medium and lysis buffer: 1
    • lysate system and lysis buffer: 1